Cetrelimab

TAR-200 monotherapy shows 83.5% complete response rate in BCG-unresponsive HR-NMIBC patients, with 82% maintaining response after 9.2 months, highlighting its potential as a bladder-sparing treatment alternative to radical cystectomy.

TAR-200 monotherapy shows 83.5% complete response rate in BCG-unresponsive HR-NMIBC patients, with 82% maintaining response after 9 months.

Johnson & Johnson announces Phase 2b SunRISe-1 study results showing 84% complete response rate with TAR-200 for BCG-unresponsive high-risk non-muscle-invasive bladder cancer, presented at ESMO 2024.

Updated MARIPOSA-2 study results show RYBREVANT® plus chemotherapy significantly improves post-progression outcomes in previously treated NSCLC patients with EGFR exon 19 deletions or L858R mutations, with a favorable trend toward improved overall survival compared to chemotherapy alone. Data presented at ESMO 2024 Congress.

RYBREVANT® (amivantamab-vmjw) + chemotherapy showed promising antitumor activity in RAS/BRAF WT mCRC patients not previously treated with anti-EGFR therapy, with a median duration of response of 7.4 months. 21% of patients proceeded to curative-intent surgery.

Pre-medication with dexamethasone reduces infusion-related reaction rate with intravenous RYBREVANT® by three-fold in EGFR-mutated advanced NSCLC patients.

Johnson & Johnson presents new findings on RYBREVANT® for lung and colorectal cancers, TAR-200 for bladder cancer at WCLC and ESMO 2024. Highlights include RYBREVANT®'s efficacy in EGFR-mutated NSCLC and its potential in metastatic colorectal cancer, alongside TAR-200's organ-sparing therapy for bladder cancer.

Johnson & Johnson presents new findings on RYBREVANT® for lung and colorectal cancers, TAR-200 for bladder cancer, and other treatments at WCLC and ESMO 2024. Highlights include RYBREVANT®'s efficacy in EGFR-mutated NSCLC and its potential in metastatic colorectal cancer, alongside TAR-200's organ-sparing therapy for bladder cancer.